NHL Cyberfamily

Non-Hodgkin's lymphoma support

 

American society of hematology 2015



 

Lymphoma abstracts from the American Society of Hematology (ASH) 2015 convention in Orlando Florida

ASH abstract home page

Click on any of the categories below to get a list of abstracts on that topic from the 2015 ASH convention. There is an outstanding amount of good information in these abstracts.

Better still, use the search box at the bottom. Fill in any terms of interest and find only abstracts from the 2015 convention that have those terms.

622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Bench to Bedside - Tools in Sight of Clinical Practice

622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Clinical Implications of Genomic Studies of B-cell Lymphomas

622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Deregulated Signaling Mechanisms in Lymphoid Malignancies

622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Genomic and Epigenetic Landscapes of Lymphoid Malignancies

622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: New Targets In Aggressive Lymphoma

622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Refining The Molecular Roadmap In NHL

623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Aggressive NHL - MCL, Burkitt, T-cell

623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: DLBCL - Beyond R-CHOP

623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: NHL - New Drugs

623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Response Adapted Therapy and New Combinations in Hodgkin Lymphoma

624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Biologic Agents in B Cell Lymphoma

624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Biologic Agents in Hodgkin Lymphoma

624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Novel Immunotherapy Strategies in Lymphoma

701. Experimental Transplantation: Basic Biology, Engraftment, and Disease Activity

702. Experimental Transplantation: Immune Function, GVHD, and Graft-versus-Tumor Effects: Novel Approaches to Dampen GVHD

702. Experimental Transplantation: Immune Function, GVHD, and Graft-versus-Tumor Effects: Shifting the Balance Between GVH, GVT, and Post-transplant Immunity

703. Adoptive Immunotherapy: Clinical Studies

721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Clinical and Biological Prognostic Markers, Donor Mobilization, Supportive Care

721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Pediatric Studies and Interventional Studies for Viral Infections

721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Regimens and Early Complications - Results of Prospective and Retrospective Studies

722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Biological Studies

722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Trials

723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Late Complications and Immune Evasion

723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Relapse

731. Clinical Autologous Transplantation: Results I

731. Clinical Autologous Transplantation: Results II

731. Clinical Autologous Transplantation: Results III

732. Clinical Allogeneic Transplantation: Results I

732. Clinical Allogeneic Transplantation: Results II

732. Clinical Allogeneic Transplantation: Results: Matched Related, Unrelated, and Alternative Donor Allograft Outcomes for Myeloid and Lymphoid Malignancies

732. Clinical Allogeneic Transplantation: Results: New Insights Into the Biology of Allogeneic Transplantation

 

You can also search for any specific word or drug or title from the 2015 abstracts using the search box below. Your search will be limited to the 2015 ASH abstracts.